Juvenile metachromatic leukodystrophy 10 years post transplant compared with a non-transplanted cohort
Standard
Juvenile metachromatic leukodystrophy 10 years post transplant compared with a non-transplanted cohort. / Krägeloh-Mann, I; Groeschel, S; Kehrer, C; Opherk, K; Nägele, T; Handgretinger, R; Müller, I.
in: BONE MARROW TRANSPL, Jahrgang 48, Nr. 3, 01.03.2013, S. 369-75.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Juvenile metachromatic leukodystrophy 10 years post transplant compared with a non-transplanted cohort
AU - Krägeloh-Mann, I
AU - Groeschel, S
AU - Kehrer, C
AU - Opherk, K
AU - Nägele, T
AU - Handgretinger, R
AU - Müller, I
PY - 2013/3/1
Y1 - 2013/3/1
N2 - Metachromatic leukodystrophy (MLD) is a rare inborn error of metabolism leading to severe neurological symptoms and early death. Hematopoietic SCT (HSCT) is considered a treatment option, but results are inconsistent and comparison with natural history is practically missing. We compare a girl with juvenile MLD 10 years after allogeneic HSCT not only with her untreated sister, but also with a large cohort of untreated patients. The girl received HSCT at the age of 5 years when first motor signs appeared. Over 10 years she was stable with respect to her clinical course and gained cognitive abilities. Magnetic resonance imaging (MRI) showed clear regression of white matter changes and magnetic resonance spectroscopy (MRS) demonstrated a reversal of the initial choline increase and N-acetyl-aspartate (NAA) decrease. Only axonal demyelinating neuropathy showed some progression. Her gross motor function and MRI-scores were clearly better compared with her sister and the cohort of untreated patients. Difference to her sister became apparent only 4 years after HSCT. We conclude that HSCT, early in the course of disease, can lead to stabilization of juvenile MLD with a course clearly different from the natural history. HSCT may prevent disease progression, if performed sufficient time before loss of walking, which typically initiates rapid deterioration.
AB - Metachromatic leukodystrophy (MLD) is a rare inborn error of metabolism leading to severe neurological symptoms and early death. Hematopoietic SCT (HSCT) is considered a treatment option, but results are inconsistent and comparison with natural history is practically missing. We compare a girl with juvenile MLD 10 years after allogeneic HSCT not only with her untreated sister, but also with a large cohort of untreated patients. The girl received HSCT at the age of 5 years when first motor signs appeared. Over 10 years she was stable with respect to her clinical course and gained cognitive abilities. Magnetic resonance imaging (MRI) showed clear regression of white matter changes and magnetic resonance spectroscopy (MRS) demonstrated a reversal of the initial choline increase and N-acetyl-aspartate (NAA) decrease. Only axonal demyelinating neuropathy showed some progression. Her gross motor function and MRI-scores were clearly better compared with her sister and the cohort of untreated patients. Difference to her sister became apparent only 4 years after HSCT. We conclude that HSCT, early in the course of disease, can lead to stabilization of juvenile MLD with a course clearly different from the natural history. HSCT may prevent disease progression, if performed sufficient time before loss of walking, which typically initiates rapid deterioration.
KW - Adolescent
KW - Cohort Studies
KW - Disease Progression
KW - Female
KW - Hematopoietic Stem Cell Transplantation
KW - Humans
KW - Leukodystrophy, Metachromatic
KW - Male
KW - Treatment Outcome
U2 - 10.1038/bmt.2012.155
DO - 10.1038/bmt.2012.155
M3 - SCORING: Journal article
C2 - 22941383
VL - 48
SP - 369
EP - 375
JO - BONE MARROW TRANSPL
JF - BONE MARROW TRANSPL
SN - 0268-3369
IS - 3
ER -